Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing promise in early trials and lab tests. How the new drug works in the ...

Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease. The drug, a peptide inhibitor called RI-AG03, successfully ...

Scientists have developed a novel peptide that could potentially revolutionize the treatment of Alzheimer's disease and other neurodegenerative disorders known as tauopathies.

The increasing knowledge on how protein tau is organized in live cells has shown that the protein forms nanometer-sized hotspots which are different from tau microtubules. These hotspots, essential ...

A new drug, RI-AG03, developed by researchers at the University of Southampton, targets two critical regions of the tau protein linked to Alzheimer's disease. Early tests demonstrated the drug's ...

The study found that the medication, called RI-AG03, was effective at preventing the build-up of Tau proteins in both laboratory and fruit fly studies. Lead author Dr Anthony Aggidis, former ...

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer’s Disease. For the first time, scientists have developed a drug that ...

Alzheimer's disease is a neurodegenerative condition that affects an estimated 7 million Americans.